Want to see ABSI full AI Analyst Report?
ABSI Stock Chart & Stats
$3.58
$0.12(3.91%)
At close: 4:00 PM EST
$3.58
$0.12(3.91%)
Day’s Range― - ―
52-Week Range$2.24 - $12.06
Previous CloseN/A
Volume51.94M
Average Volume (3M)6.73M
Market Cap
$1.41B
Enterprise Value$337.60
Total Cash (Recent Filing)$125.70M
Total Debt (Recent Filing)$4.42M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Aug 11, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding169,400,330
10 Day Avg. Volume4,670,384
30 Day Avg. Volume6,728,175
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.52
Price to Sales (P/S)170.48
P/FCF Ratio-5.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.38Price Target Upside273.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$5.74M
Bulls Say, Bears Say
Bulls Say
AI + Wet‑lab PlatformAbSci’s combined agentic AI and high-throughput wet‑lab model is a durable competitive asset: it supports faster design iterations, repeatable service engagements, and platform leverage across programs, increasing the likelihood of sustained partnerships and licensing revenue over time.
Low Financial LeverageVery low debt materially reduces refinancing and solvency risk for an R&D-heavy biotech. It gives the company strategic optionality to fund programs through equity, partnerships, or selective financings without near-term debt pressure, supporting multi‑quarter development execution.
Clinical Progress On ABS‑201Favorable Phase I safety/PK and long half‑life that supports infrequent dosing are structurally important: they improve product differentiation, commercial convenience, and payor/commercial prospects. If POC is confirmed, this materially enhances the platform’s path to partnering or internal commercialization.
Bears Say
High Cash BurnSustained negative operating and free cash flow at ~‑$100M TTM creates a persistent funding requirement. Over multiple quarters this elevates dilution or partnership dependency risk and forces management to prioritize capital allocation, potentially slowing program breadth or timelines.
Minimal And Declining RevenueExtremely low and falling revenue means the company cannot self‑fund R&D from operations. Dependence on financings and milestone payments increases execution sensitivity and may compress runway if fundraising windows tighten, limiting long‑term independence.
Clinical & Placebo RiskHigh placebo rates and pending definitive efficacy readouts create durable execution risk: negative or ambiguous POC results could delay registrational plans, reduce partnering interest, and materially alter commercial prospects even if early safety/PK remain positive.
AbSci News
ABSI FAQ
What was Absci Corp.’s price range in the past 12 months?
Absci Corp. lowest stock price was $2.24 and its highest was $12.05 in the past 12 months.
What is Absci Corp.’s market cap?
Absci Corp.’s market cap is $1.41B.
When is Absci Corp.’s upcoming earnings report date?
Absci Corp.’s upcoming earnings report date is Aug 11, 2026 which is in 21 days.
How were Absci Corp.’s earnings last quarter?
Absci Corp. released its earnings results on May 07, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.199 by $0.009.
Is Absci Corp. overvalued?
According to Wall Street analysts Absci Corp.’s price is currently Undervalued.
Does Absci Corp. pay dividends?
Absci Corp. does not currently pay dividends.
What is Absci Corp.’s EPS estimate?
Absci Corp.’s EPS estimate is -0.19.
How many shares outstanding does Absci Corp. have?
Absci Corp. has 169,400,330 shares outstanding.
What happened to Absci Corp.’s price movement after its last earnings report?
Absci Corp. reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.199. Following the earnings report the stock price went up 2.609%.
Which hedge fund is a major shareholder of Absci Corp.?
Currently, no hedge funds are holding shares in ABSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbSci Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.38 (273.60% Upside)
$13.38 (273.60% Upside)
Blogger Sentiment
Bullish
ABSI Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth $349.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 9.2%
Last 30 Days ▲ 9.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
188.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.85%
Trailing 12-Months
Company Description
Absci Corp.
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
ABSI Stock 12 Month Forecast
Average Price Target
$13.38
▲(273.60% Upside)
Technical Analysis
Autolus Therapeutics
―
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
6.13% Insiders
17.83% Mutual Funds
0.09% Other Institutional Investors
56.39% Public Companies and
Individual Investors